Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial

BACKGROUND: Glioblastoma (GBM), the most lethal primary brain tumor, has limited treatment options upon recurrence after chemoradiation and bevacizumab. TRC105 (carotuximab), a chimeric anti-endoglin (CD105) antibody, inhibits angiogenesis and potentiates activity of VEGF inhibitor bevacizumab in pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahluwalia, Manmeet S., Rogers, Lisa R., Chaudhary, Rekha, Newton, Herbert, Ozair, Ahmad, Khosla, Atulya A., Nixon, Andrew B., Adams, Bonne J., Seon, Ben K., Peereboom, David M., Theuer, Charles P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491825/
https://www.ncbi.nlm.nih.gov/pubmed/37684373
http://dx.doi.org/10.1038/s43856-023-00347-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491825/
https://www.ncbi.nlm.nih.gov/pubmed/37684373
http://dx.doi.org/10.1038/s43856-023-00347-0

Ejemplares similares